Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen in siRNA Agreement with AstraZeneca

NEW YORK, July 1 (GenomeWeb News) - Qiagen will supply siRNA molecules to AstraZeneca under an agreement announced today.

 

Financial details were not disclosed.

 

The products in the agreement were not part of the spinoff of Qiagen's DNA business, which was announced earlier (click here to see story).

The Netherlands-based Qiagen employs a proprietary design process based on TOM-amidites to produce its siRNA molecules.